# BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants

Source: https://onco.cc/trials/nct05943106/  
OnCo record `nct05943106` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Durvalumab in bladder & urothelial cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants is a phase 3 interventional study registered as NCT05943106 by AstraZeneca, with 100 participants enrolled, started 2023-08-11 and due to reach its primary completion in 2025-06-16. Interventions recorded: Durvalumab and BCG.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05943106
- Phase: 3
- Setting: A Phase IIIb Open-Label, Single-Arm, Multi-Center, US Study of Bacillus Calmette-Guerin (BCG) Administered in Combination With Durvalumab in Adult BCG-naïve, High-risk Non-Muscle- Invasive Bladder Cancer Participants (PATAPSCO)
- Sponsor: AstraZeneca
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT05943106: https://clinicaltrials.gov/study/NCT05943106

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Durvalumab](https://onco.cc/drugs/durvalumab/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/), [Parexel](https://onco.cc/companies/parexel/)

---
JSON: https://onco.cc/api/v1/entities/nct05943106.json